Simultaneous development of Graves ’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report

We present the first case of simultaneous development of Graves ’ disease and type 1 diabetes during anti‐programmed cell death 1 therapy. Among Japanese participants with autoimmune polyglandular syndrome type III, the frequency of human leukocyte antigen‐DRB1*04:05 is higher in those with both type 1 diabetes and Graves’ disease. The present partic ipant carried the human leukocyte antigen‐DRB1*04:05; which might be associated with the simultaneous development of the two diseases. AbstractWe present the first case of simultaneous development of Graves ’ disease and type 1 diabetes during anti‐programmed cell death 1 therapy. A 48‐year‐old man with parotid gland adenocarcinoma and lung metastasis had received five courses of nivolumab. Fourteen days after administration of the sixth course, his casual plasma glucose and hemoglobin A1c l evels were 379 mg/dL and 7.2%, respectively. Furthermore, thyrotoxicosis was detected with a blood test. Serum total ketone body and thyroid‐stimulating hormone receptor antibody levels increased, and serum C‐peptide level decreased to 0.01 ng/mL thereafter. Thus, we concluded that he simultan eously developed anti‐programmed cell death 1 therapy‐associated type 1 diabetes and Graves’ disease. Among Japanese patients with autoimmune polyglandular syndrome type III, the frequency of human leukocyte antigen‐DRB1*04:05 is higher in those with both type 1 diabetes and Graves’ di sease. Our case had hum...

Source: Journal of Diabetes Investigation - February 19, 2020 Category: Endocrinology Authors: Susumu Kurihara, Yoichi Oikawa, Ritsuko Nakajima, Atsushi Satomura, Ryuhei Tanaka, Hiroshi Kagamu, Akira Shimada Tags: Case Report Source Type: research